TEAM

The founder partners of Eudendron are well experienced in Drug Discovery with a focus on Drug Design, Medicinal Chemistry and Computational Chemistry. The technical/scientific and managerial competences of the Eudendron Team are demonstrated by more than 40 scientific publications on international journals and 20 national patents – subsequently extended to other countries (e.g. USA, Canada, Japan, Europe) – produced by the founder partners.

Mauro Angiolini
Managing Director

mauro.angiolini@eudendron.com

Fabio Zuccotto
Managing Director

fabio.zuccotto@eudendron.com

Mauro Angiolini received in 1995 a Laurea degree in Chemistry and a Ph.D. in Medicinal Chemistry in 1998, working under the supervision of Prof. Carlo Scolastico at the Universita degli Studi, Milano, Italy. He joined Pharmacia & Upjohn in Nerviano (later Nerviano Medical Sciences) where he has been involved in many projects related to the discovery of new drugs in the oncology therapeutic area, with considerable focus on kinases inhibitors. In 2000 he spent one year as postdoctoral fellow in Prof. S. Hanessian group at Universite de Montreal, Canada, focusing on application of the ring closing metathesis reaction. 

Fabio Zuccotto obtained a Laurea degree in Chemistry from Universita degli Studi, Milan, Italy, under the supervision of Prof. A. Bernardi and in 1998 a Ph.D. in Medicinal Chemistry from the Welsh School of Pharmacy in Cardiff, U.K., under the supervision of Prof. I. H. Gilbert. He was a postdoctoral researcher in Prof. G. Roberts’ group at the Centre for Mechanisms of Human Toxicity of Leicester University, U.K., and at GlaxoWellcome, Stevenage, U.K., with Dr. A. Leach. In 2001 he joined Inpharmatica, London, U.K., working in the Molecular Design Group as Senior Scientist. In 2006 he moved to Nerviano Medical Sciences, Nerviano, Italy, where he was Principal Scientist and Team/Project Leader with responsibilities in the Computational Chemistry and Fragment Based Drug Discovery areas, working in kinase and non-kinase oncology-related targets.